Anti-idiotypic antibodies: from regulation to therapy of factor VIII inhibitors.
Evidence has recently accumulated showing that anti-idiotypic antibodies specific to anti-FVIII antibodies are present in the plasma of healthy individuals and of haemophilia A patients with or without inhibitors, where they can neutralise the FVIII inhibitory activity. Additionally, patients successfully desensitised towards FVIII have an increased production of anti-idiotypic antibodies with no significant reduction in anti-FVIII antibodies. We review here possible strategies for modulating the anti-FVIII immune response by idiotypic interactions.
Saint-Remy
J M
JM
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
Jacquemin
M G
MG
Gilles
J G
JG
D000888:Antibodies, Anti-Idiotypic / Q000737:chemistry / Q000627:therapeutic use*; D001323:Autoantibodies / Q000737:chemistry; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007108:Immune Tolerance; D007130:Immunoglobulin Idiotypes / Q000737:chemistry*; D007518:Isoantibodies / Q000737:chemistry; D008297:Male
D000888:Antibodies, Anti-Idiotypic; D001323:Autoantibodies; D007130:Immunoglobulin Idiotypes; D007518:Isoantibodies; D005169:Factor VIII